# The Procter & Gamble Company (PG) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Consumer Defensive / Household Products. Price $146.44, market value $340.1 billion.

## Valuation
- **P/E (trailing): 22.1×** (5-yr avg 23.4×, 3-yr avg 23.8×). The Procter & Gamble Company trades at 22.1× trailing earnings, close to its own five-year average of 23.4×. The Consumer Defensive median in the September 2026 study was 20.1×. Forward P/E is 19.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 11.71**. A PEG of 11.71 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 3.9×**. Each dollar of revenue is priced at 3.9×.
- **Price / book: 6.4×**. The shares trade at 6.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 16.3×**. Enterprise value is 16.3× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 4.5%** (5-yr avg 4.1%). Free cash flow equals 4.5% of the market value, in line with its five-year average of 4.1%.
- **Earnings yield: 4.5%**. The inverse of the P/E: 4.5% of the price is earned each year.

## Profitability
- **Operating margin: 22.7%**. 22.7% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 18.4%**. 18.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 29.5%**. 29.5% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 17.6%**. Return on all capital, debt included, is 17.6%: comfortably above what that capital costs.
- **Return on assets: 12.7%**. Each dollar of assets produces 12.7% of profit.

## Growth
- **Revenue growth (1 yr): 3.3%** (3-yr 2.0%/yr, 5-yr 2.7%/yr). Revenue grew 3.3% over the last year, against 2.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 1.7%** (3-yr 3.9%/yr, 5-yr 3.8%/yr). Earnings per share rose 1.7%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 3.2%/yr**. Free cash flow has compounded at 3.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.63**. Debt is 0.63 times equity, moderate leverage.
- **Current ratio: 0.68** (quick 0.68). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: 4.51**. A Z-score of 4.51 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.97%** ($4.26 per share, trailing). The Procter & Gamble Company yields 2.97%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 64%** (68% of free cash flow). 64% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 22**. 22 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 6.0%/yr** (1-yr 5.5%). The dividend has grown 6.0% a year over five years.

## Analyst view
- **Analyst consensus: buy** (23 analysts). 23 analysts cover The Procter & Gamble Company; the consensus is buy, with an average price target of $160.61 (+10% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -5.3%** (YTD 4.5%, 3-mo 0.7%). The shares are down 5.3% over twelve months including dividends.
- **From 52-week high: -12.4%** (6.4% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): -0.05** (volatility 20%). Beta of -0.05 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PG · Page: https://foliofundamentals.com/stocks/pg

Not investment advice.